

In the Specification:

Page, 18, lines 1-11, please amend the paragraph as follows:

*a1* The insulin agent, i.e. insulin, biologically active variant thereof, or agent that can enhance the effect or levels of insulin levels upon administration, may be a variety of therapeutics. Preferred biologically active variants of insulin are discussed below. Suitable agents that enhance insulin effects or levels include e.g. sulfonylureas such as glipizide, and thiazolidinediones such as rosiglitazone. PPAR-gamma receptors agonists in addition to thiazolidinediones also will be suitable. Suitable agents that can enhance insulin effects and insulin levels also are disclosed in e.g. U.S. Patents Nos. 5,489,602; 5,811,439; 5,965,589; and 5,972,973. Methods for identifying additional agents that enhance insulin effects and insulin levels are disclosed in U.S. Patents Nos. 5,466,610 and 6,100,047 6,100,047.

Page 19, line 16, please amend the paragraph as follows:

*a2* wherein in formula II, R<sup>1</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl; R<sup>2</sup> is H,  $\pm$  methyl or ethyl;

Page 20, lines 6 and 7, please amend the paragraph as follows:

*a3* and R<sup>8</sup> is H; C<sub>1</sub>-C<sub>3</sub> alkyl or (hydroxy)C<sub>2</sub>-C<sub>3</sub> alkyl; and pharmaceutically acceptable salts thereof.

Page 26, lines 5 and 6, please amend the paragraph as follows:

*a4* R<sup>1</sup> represents hydrogen, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, haloC<sub>1-6</sub>alkyl, C<sub>3-8</sub> C<sub>3-8</sub> cycloalkyl, C<sub>3-8</sub> C<sub>3-8</sub> cycloalkylC<sub>1-3</sub>alkyl, arylC<sub>1-3</sub>alkyl, or heteroarylC<sub>1-3</sub>alkyl;

Page 26, lines 18-20, please amend the paragraph as follows:

*a5* R<sup>3</sup> represents hydrogen ~~or~~ or C<sub>1-3</sub> alkyl, or R<sup>1</sup> and R<sup>3</sup> together represents a 3- or 4-membered alkyl or alkenyl chain; and pharmaceutically and acceptable salts and solvates (e.g., hydrates) thereof. Examples of solvates include hydrates.

Page 27, lines 5 and 6, please amend the paragraph as follows:

a<sup>b</sup>

R<sup>1</sup> represents hydrogen, C<sub>1-6</sub> alkyl, haloC<sub>1-6</sub>alkyl, G<sub>3-8</sub> C<sub>3-8</sub> cycloalkyl, aryIC<sub>1-3</sub>alkyl, or heteroarylC<sub>1-3</sub>alkyl;

Page 27, lines 13-17, please amend the paragraph as follows:

a<sup>7</sup>

attached to the rest of the molecule via one of the benzene ring carbon atoms, and wherein the fused ring A is 5- or 6-membered ring which can be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur, and nitrogen; and pharmaceutically acceptable salts and solvates (e.g., hydrates) thereof. Examples of solvates include hydrates.

a<sup>8</sup>

Page 28, lines 11 and 12, please amend the paragraph as follows:

R<sup>3</sup> represents hydrogen or C<sub>1-3</sub> alkyl; and pharmaceutically acceptable salts and solvates (e.g., hydrates) thereof. Examples of solvates include hydrates.

a<sup>9</sup>

Page 32, lines 1-5, please amend the paragraph as follows:

and mixtures thereof with their cis optical enantiomers, including racemic mixtures, and salts and solvates (e.g., hydrates) of these compounds in which R<sup>0</sup> is hydrogen or halogen (e.g., fluorine), especially hydrogen, and R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> are as defined previously. Examples of solvates include hydrates. Examples of halogen include fluorine.

a<sup>10</sup>

Page 35, lines 7 and 8, please amend the paragraph as follows:

R<sup>1</sup> represents hydrogen, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, haloC<sub>1-6</sub>alkyl, G<sub>3-8</sub> C<sub>3-8</sub> cycloalkyl, G<sub>3-8</sub> C<sub>3-8</sub> cycloalkylC<sub>1-3</sub>alkyl, aryIC<sub>1-3</sub>alkyl or heteroarylC<sub>1-3</sub>alkyl;

a<sup>11</sup>

Page 35, lines 20-22, please amend the paragraph as follows:

R<sup>3</sup> represents hydrogen or C<sub>1-3</sub> alkyl, or R<sup>1</sup> and R<sup>2</sup> together represent a 3- or 4-membered alkyl or alkenyl chain; and pharmaceutically acceptable solvates (e.g., hydrates) thereof. Examples of solvates includes hydrates.

Page 39, line 20, please amend the paragraph as follows:

a<sup>12</sup> and pharmaceutically acceptable salts and solvates (e.g., hydrates) thereof.  
Examples of solvates include hydrates.

Page 41, line 13, please amend the paragraph as follows:

a<sup>13</sup> and pharmaceutically acceptable salts and solvates (e.g., hydrates) thereof.  
Examples of solvates include hydrates.